Identifying an Optimal Corticosteroid Dosage Regimen for Acute Respiratory Distress Syndrome

Recruiting Phase 4 Interventional Study
Acute Respiratory Distress Syndrome (ARDS)
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 4
Study type
Interventional
Purpose
Treatment
Participants needed
300 (estimated)
Sponsor
National Taiwan University Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The early phase of Acute Respiratory Distress Syndrome (ARDS) is characterized by intense alveolar inflammation. Corticosteroids have been used to treat ARDS for decades. Although their efficacy has been a subject of ongoing controversy, recent clinical practice guidelines for ARDS issued a weak recommendation in favor of corticosteroid use in early ARDS. However, the optimal dose and duration of …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * ARDS (as defined by the Berlin definition) with an FiO₂ of 0.5 or higher * On invasive mechanical ventilation * Duration of intubation less than three days Exclusion Criteria: * Age less than 18 years * Required to receive steroids or considered ineligible for steroids by th…
Contacts

Sheng-Yuan Ruan, MD, PhD

886223123456

syruan@ntu.edu.tw

CONTACT